Related Experiment Videos
Left ventricular hypertrophy regression during antihypertensive treatment
H Eichstaedt1, O Danne, R J Schroeder
1Department of Cardiology, University Hospital Rudolf Virchow, Free University of Berlin.
The Clinical Investigator
|January 1, 1992
Summary
Left ventricular hypertrophy regression is challenging in humans. This study demonstrates significant hypertrophy regression in hypertensive patients treated with Carvedilol for six months.
Area of Science:
- Cardiology
- Hypertension Research
- Medical Treatment
Background:
- Left ventricular hypertrophy (LVH) regression is a key area in hypertension research.
- Animal studies show LVH reduction with hypertension treatment, more effectively in younger subjects.
- Regression of LVH in humans is difficult to demonstrate conclusively.
Purpose of the Study:
- To investigate the efficacy of Carvedilol in achieving left ventricular hypertrophy regression in hypertensive patients.
- To assess the feasibility of demonstrating LVH regression in a clinical setting.
Main Methods:
- Utilized magnetic resonance imaging (MRI) for accurate assessment of left ventricular muscle mass and hypertrophy.
- Clinical study involving hypertensive patients treated with Carvedilol.
- Evaluation period of six months of medical treatment.
Main Results:
- Demonstrated significant regression of left ventricular hypertrophy after six months of Carvedilol treatment.
- Magnetic resonance imaging confirmed the accuracy in assessing hypertrophy and its regression.
- Echocardiography showed potential but MRI provided superior imaging quality.
Conclusions:
- Carvedilol treatment can effectively induce left ventricular hypertrophy regression in hypertensive patients.
- Advanced imaging techniques like MRI are crucial for accurately measuring LVH regression.
- Hypertrophy regression in humans is achievable with appropriate medical intervention.